Cargando…

A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin

BACKGROUND: To assess the effect of fidaxomicin and vancomycin on Clostridium difficile toxins and correlation with clinical and microbiologic outcomes. METHODS: Hospitalized patients with C. difficile infection were randomly assigned a 10-day course of fidaxomicin or vancomycin. Stool samples colle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thabit, Abrar K., Alam, M. Jahangir, Khaleduzzaman, Mohammed, Garey, Kevin W., Nicolau, David P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830079/ https://www.ncbi.nlm.nih.gov/pubmed/27071986 http://dx.doi.org/10.1186/s12941-016-0140-6

Ejemplares similares

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)

Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection
por: Bassères, Eugénie, et al.
Publicado: (2016)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
por: Weiss, Karl, et al.
Publicado: (2012)

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
por: Cornely, Oliver A., et al.
Publicado: (2012)

Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection
por: Nathwani, Dilip, et al.
Publicado: (2014)

Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
por: Lee, Christine, et al.
Publicado: (2016)

Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin
por: Figueroa, Iris, et al.
Publicado: (2012)

Lack of Correlation between Bristol Stool Scale and Quantitative Bacterial Load in Clostridium difficile Infection
por: Thabit, Abrar K, et al.
Publicado: (2015)

Fidaxomicin Inhibits Spore Production in Clostridium difficile
por: Babakhani, Farah, et al.
Publicado: (2012)

Fidaxomicin - the new drug for Clostridium difficile infection
por: Vaishnavi, Chetana
Publicado: (2015)

Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
por: Crook, Derrick W., et al.
Publicado: (2012)

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses
por: Cornely, Oliver A., et al.
Publicado: (2019)

A multi-center study of fidaxomicin use for Clostridium difficile infection
por: Shah, Dhara N., et al.
Publicado: (2016)

Community Environmental Contamination of Toxigenic Clostridium difficile
por: Alam, M Jahangir, et al.
Publicado: (2017)

Whole-Genome Sequencing Demonstrates That Fidaxomicin Is Superior to Vancomycin for Preventing Reinfection and Relapse of Infection With Clostridium difficile
por: Eyre, David W., et al.
Publicado: (2014)

Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
por: Chaparro-Rojas, Fredy, et al.
Publicado: (2013)

Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile Infection
por: Nerandzic, Michelle M., et al.
Publicado: (2012)

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI
por: Sattar, Abdul, et al.
Publicado: (2015)

Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection
por: Zhanel, George G, et al.
Publicado: (2015)

Fidaxomicin Use and Clinical Outcomes for Clostridium difficile–Associated Diarrhea
por: Eiland, Edward H., et al.
Publicado: (2015)

An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes
por: Thabit, Abrar K, et al.
Publicado: (2016)

682. Novel rpoB mutations and trends in clinical Clostridioides difficile isolates with reduced fidaxomicin susceptibility
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections
por: Mullane, Kathleen M., et al.
Publicado: (2011)

Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review
por: Al Momani, Laith A, et al.
Publicado: (2018)

Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea
por: Weiss, Karl, et al.
Publicado: (2015)

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness
por: Cornely, Oliver A, et al.
Publicado: (2018)

Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain
por: Rubio-Terrés, Carlos, et al.
Publicado: (2019)

722. Effectiveness of Fidaxomicin versus Oral Vancomycin in the Treatment of Recurrent Clostridioides difficile
por: Rinaldi, Alyssa, et al.
Publicado: (2020)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

679. Retrospective Analysis of Vancomycin and Fidaxomicin for the Treatment of Recurrent Clostridioides difficile Infection
por: Fabian, Amy, et al.
Publicado: (2023)

Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland
por: van Engen, Anke, et al.
Publicado: (2015)

Fidaxomicin for Clostridium difficile-Associated Diarrhoea: Epidemiological Method for Estimation of Warranted Price
por: Sclar, David Alexander, et al.
Publicado: (2012)

467 Analysis of Clinical and Economical Outcomes of Fidaxomicin Use for Clostridium difficile infections
por: Flaherty, Sarah, et al.
Publicado: (2014)

Fidaxomicin Use for Clostridium Difficile Infection Probably Decreases the Effect of Coumadin® in Elderly
por: Dhruv, Samyak, et al.
Publicado: (2020)

Fidaxomicin for the Treatment of Clostridium Difficile Infection in the Pediatric Population - Not Quite So Soon Yet
por: Daniels, Tanya, et al.
Publicado: (2011)

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
por: Louie, Thomas J., et al.
Publicado: (2012)

Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
por: Jiang, Yiling, et al.
Publicado: (2022)

The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
por: Hall, Ronald G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dq2l64fo20c1skt0jel7sm5ka5